Adipokines demonstrate the interacting influence of central obesity with other cardiometabolic risk factors of metabolic syndrome in Hong Kong Chinese adults.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Adipokines/*blood ; Metabolic Syndrome/*metabolism ; Obesity, Abdominal/*metabolism; Adiponectin/blood ; Aged ; Cardiovascular Diseases ; Female ; Hong Kong ; Humans ; Insulin/blood ; Leptin/blood ; Male ; Metabolic Syndrome/blood ; Metabolic Syndrome/etiology ; Middle Aged ; Obesity, Abdominal/blood ; Obesity, Abdominal/complications ; Risk Factors ; Tumor Necrosis Factor-alpha/blood

Objective: Metabolic syndrome (MetS) or prediabetes is a complex disorder that is defined by a clustering of cardiometabolic risk factors, including obesity, hypertriglyceridemia, reduced high-density lipoprotein (HDL) cholesterol, hypertension, and insulin resistance. Among cardiometabolic risk factors, central obesity plays a key role in the development of MetS through alterations in the secretion of adipokines and interacts with other MetS risk factors to unfavorably influence overall cardiometabolic risk. Obesity has grasped epidemic proportions in Asia, which has the highest number of people with diabetes in the world. But, the importance of central obesity in the clustering of all four MetS risk factors or vice versa in predicting severity of MetS has not yet been investigated in Asian population. Therefore, the present study examined the influence of central obesity on circulating levels of adipokines through its interaction with the clustering of cardiometabolic risk factors of MetS including hyperglycemia, hypertriglyceridemia, dyslipidemia and hypertension in Hong Kong Chinese adults.
Subjects: Blood samples from 83 Hong Kong Chinese adults, who were previously screened for MetS according to the guideline of the United States National Cholesterol Education Program Expert Panel Adult Treatment Panel III criteria were selected. Insulin and adipokines, including visfatin, chemerin, plasminogen activator inhibitor-1 (PAI-1), resistin, C-C motif chemokine ligand 2 (CCL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumour necrosis factor-α (TNF-α), leptin and adiponectin were assessed.
Results: The interacting effect of central obesity with all of the other four MetS risk factors increased the proinflammatory status of adipokines (TNF-α, leptin) and decreased the anti-inflammatory status of adipokine (adiponectin).
Conclusion: Our results indicate that the inflammatory status of MetS may be more severe in the presence of central obesity. Adipokines, as biomarkers for pathophysiological changes, may help to improve early patient identification and to predict MetS-associated morbidity and mortality.
Competing Interests: The authors have declared that no competing interests exist.

Rev Port Cardiol. 2012 Nov;31(11):711-9. (PMID: 23040870)
PLoS One. 2016 Apr 21;11(4):e0154003. (PMID: 27101398)
J Clin Invest. 1995 May;95(5):2409-15. (PMID: 7738205)
Life Sci. 2017 Feb 1;170:56-63. (PMID: 27919820)
Circulation. 2005 Oct 25;112(17):2735-52. (PMID: 16157765)
J Immunol Res. 2014;2014:343746. (PMID: 24741591)
Obesity (Silver Spring). 2006 Dec;14(12):2127-31. (PMID: 17189537)
Klin Lab Diagn. 2014 Jun;(6):27-38. (PMID: 25335398)
Diabetol Metab Syndr. 2015 Dec 10;7:111. (PMID: 26692905)
Front Physiol. 2018 Mar 27;9:294. (PMID: 29636702)
Hypertension. 2004 Jun;43(6):1318-23. (PMID: 15123570)
J Anim Sci. 1998 May;76(5):1405-20. (PMID: 9621947)
J Clin Endocrinol Metab. 2007 Mar;92(3):1023-33. (PMID: 17164304)
Nat Rev Endocrinol. 2013 Jan;9(1):13-27. (PMID: 23165161)
J Clin Endocrinol Metab. 2002 Dec;87(12):5575-80. (PMID: 12466355)
Diabetes. 2012 Aug;61(8):1986-93. (PMID: 22688341)
Br J Nutr. 2015 Jun 28;113(12):1920-30. (PMID: 25907896)
Metabolism. 2010 Mar;59(3):424-9. (PMID: 19846168)
Circulation. 2007 Feb 27;115(8):972-80. (PMID: 17283255)
Curr Opin Pharmacol. 2006 Dec;6(6):580-5. (PMID: 16973420)
Hypertension. 2000 Jul;36(1):14-9. (PMID: 10904006)
J Diabetes Investig. 2015 Sep;6(5):527-32. (PMID: 26417409)
FASEB J. 2006 Jul;20(9):1540-2. (PMID: 16754744)
Arch Intern Med. 2008 Aug 11;168(15):1617-24. (PMID: 18695075)
J Clin Invest. 2007 Jan;117(1):175-84. (PMID: 17200717)
Diabetes Care. 2002 Jun;25(6):971-6. (PMID: 12032101)
Gut. 2005 Jun;54(6):789-96. (PMID: 15888786)
J Am Coll Cardiol. 2006 Mar 21;47(6):1093-100. (PMID: 16545636)
J Med Assoc Thai. 2004 Jun;87(6):685-93. (PMID: 15279350)
Am J Med. 2002 Mar;112(4):275-80. (PMID: 11893366)
J Biol Chem. 2007 Sep 21;282(38):28175-88. (PMID: 17635925)
Eur J Endocrinol. 2009 Aug;161(2):339-44. (PMID: 19497986)
Int J Obes Relat Metab Disord. 1995 May;19 Suppl 1:S2-5. (PMID: 7550533)
Circulation. 2009 Oct 20;120(16):1640-5. (PMID: 19805654)
Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1114-20. (PMID: 9194762)
Cardiol Res Pract. 2014;2014:943162. (PMID: 24711954)
Nat Immunol. 2014 May;15(5):423-30. (PMID: 24681566)
J Clin Invest. 2003 Dec;112(12):1821-30. (PMID: 14679177)
Trends Mol Med. 2005 Aug;11(8):344-7. (PMID: 16005682)
Int J Obes Relat Metab Disord. 2003 Jan;27(1):88-94. (PMID: 12532159)
J Clin Invest. 2006 Jul;116(7):1776-83. (PMID: 16823475)
J Clin Invest. 1996 Jan 1;97(1):37-46. (PMID: 8550848)
Pediatr Res. 2014 Aug;76(2):159-65. (PMID: 24819375)
Int J Obes Relat Metab Disord. 2004 May;28(5):674-9. (PMID: 14993913)
Annu Rev Physiol. 2010;72:219-46. (PMID: 20148674)
J Int Med Res. 2009 Nov-Dec;37(6):1803-12. (PMID: 20146878)
Annu Rev Cell Dev Biol. 2004;20:455-80. (PMID: 15473848)
Lancet. 2006 Nov 11;368(9548):1681-8. (PMID: 17098087)
Diabetes. 1998 May;47(5):699-713. (PMID: 9588440)
Nature. 1998 Oct 22;395(6704):763-70. (PMID: 9796811)
Horm Metab Res. 2002 Jul;34(7):394-9. (PMID: 12189588)
Hypertension. 2000 Aug;36(2):226-32. (PMID: 10948082)
Neuron. 2014 Sep 3;83(5):1098-116. (PMID: 25132469)
J Biol Chem. 2001 Aug 31;276(35):32531-7. (PMID: 11443108)
Placenta. 2007 Apr;28(4):305-14. (PMID: 16701870)
PLoS One. 2014 Jan 22;9(1):e86404. (PMID: 24466075)
Diabetes Care. 2004 Feb;27(2):538-46. (PMID: 14747241)
JAMA. 2009 May 27;301(20):2129-40. (PMID: 19470990)
Metabolism. 2003 Jan;52(1):73-80. (PMID: 12524665)
J Nutr. 2004 Oct;134(10):2673-7. (PMID: 15465765)
Nat Rev Immunol. 2006 Jan;6(1):44-55. (PMID: 16493426)
J Immunol. 2005 Jul 1;175(1):487-93. (PMID: 15972683)
JAMA. 2001 May 16;285(19):2486-97. (PMID: 11368702)
Metabolism. 2010 Dec;59(12):1801-8. (PMID: 20619428)
J Nutr. 2001 Oct;131(10):2692-700. (PMID: 11584092)
Cardiovasc Diabetol. 2012 Apr 26;11:43. (PMID: 22537054)
Mediators Inflamm. 2010;2010:802078. (PMID: 20671929)
Arch Physiol Biochem. 2008 Jul;114(3):183-94. (PMID: 18629684)
Science. 1992 Dec 11;258(5089):1798-801. (PMID: 1281554)
JAMA. 1993 Dec 15;270(23):2823-8. (PMID: 8133621)
Diabetes. 1988 Dec;37(12):1595-607. (PMID: 3056758)
Int J Obes (Lond). 2008 May;32(5):757-62. (PMID: 18209738)
Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1257-66. (PMID: 12171785)
Dimens Crit Care Nurs. 2004 Nov-Dec;23(6):237-43. (PMID: 15586034)
Intern Med. 2015;54(4):375-82. (PMID: 25748952)
Diabetes. 2007 Apr;56(4):1010-3. (PMID: 17287468)
Physiol Behav. 2010 Jul 14;100(5):525-34. (PMID: 20381510)
J Obes. 2010;2010:. (PMID: 20871654)
J Clin Invest. 2004 Dec;114(12):1752-61. (PMID: 15599400)
Cardiovasc Diabetol. 2014 Apr 09;13:76. (PMID: 24716628)
Asia Pac Fam Med. 2009 Apr 09;8(1):2. (PMID: 19358728)

0 (ADIPOQ protein, human)
0 (Adipokines)
0 (Adiponectin)
0 (Insulin)
0 (LEP protein, human)
0 (Leptin)
0 (TNF protein, human)
0 (Tumor Necrosis Factor-alpha)

Date Created: 20180817 Date Completed: 20190204 Latest Revision: 20230928

20240104

PMC6095502

10.1371/journal.pone.0201585

30114249